ShareValue scores for CIPLA.NSE: Valuation 58, Quality 68, Growth 39, Health 55.

Cipla Limited logo

CIPLA.NSE
NSE

Cipla Limited

₹1,477.50(+1.28%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

6% to 16%
Valuation
58
Fair Value
Price vs Value
Quality
68
Moderate
Business Strength
Growth
39
Weak
Revenue & Earnings
Health
55
Moderate
Financial Stability
Momentum
36
Bearish
Price Trend

Company Details

About

Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026